Stereotactic Body Radiotherapy or Standard of Care for Prostate Oligoprogressive Cancer

This is a single centre, interventional, randomized Phase II, two-arm prospective trial investigating if Stereotactic Body Radiotherapy (SBRT) to all sites of Oligopressive (OP) disease while remaining on current Systemic Therapy (ST) will improve biochemical control compared to Standard of Care (SoC) (which involves a change in ST) for patients with OP Castrate Resistance Prostate Cancer (CRPC).

Trial Details

NCT ID
NCT06927635
Phase
PHASE2
Sponsor
University Health Network, Toronto
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • Stereotactic Body Radiation Therapy (SBRT)
  • Systemic therapy
Locations (sample)
  • Toronto, Ontario, Canada|43.65333,-79.38389

Key Eligibility Criteria

  • Age \>18 years
  • Able to provide informed consent
  • Histologic diagnosis of prostate adenocarcinoma
  • Castrate Resistance Prostate Cancer

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →